Medicago: PhII avian flu vax trial successful

Canada's Medicago says the company's Phase II trial of its vaccine for avian flu elicited a solid immune response and was found to be safe and well tolerated. Notably, the vaccine was equally effective in older and younger subjects, which CEO Andy Sheldon could be a key selling point for the shot.

The vaccine is based on Medicago's manufacturing technologies and virus-like particles (VLPs), that allow the developer to rapidly produce more effective vaccines. Medicago is on the verge of opening a 90,000-square-foot facility in Research Triangle Park, NC to help manufacture VLP plant-based vaccine technology. The developer expects to have commercial capacity by this fall.

"...[W]e believe these results further support the effectiveness of our rapid plant-based vaccine platform and the development of our seasonal flu vaccine candidate which we intend to proceed with a U.S. clinical trial in the second half of the year," noted Sheldon in a release.

- here's Medicago's release

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.